Fourteen days on the docket: the peptide policy is published, and this is what it requires

This morning the Federal Register printed, at 91 FR 68526, a two-page notice signed by the Secretary of Health and Human Services: the department's Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. We wrote about the filing two days ago, when it existed only as a public-inspection document. Publication changes two things. It starts a fourteen-day comment period, which closes on November 13. And it puts the policy's conditions on the record in a form that can be read, quoted and held against anyone who claims its protection. Those conditions are the part of this story the headlines skipped, and they are the part that matters most to anyone who handles these molecules, in a pharmacy or in a laboratory.

What printed today

The notice itself is short. It announces the availability of a draft policy, says that written comments can be submitted until 2 weeks after date of publication on docket HHS-OASH-2026-0496 at regulations.gov, and repeats the department's reasoning: based on the Pharmacy Compounding Advisory Committee meetings and data regarding utilization of peptides, HHS believes that there is significant interest in the use of these peptides in compounding given the lack of availability of approved products. It states the limits in the same breath. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed; the policy does not establish any rights for any person and is not binding on HHS or the public; and HHS may revisit application of this interim policy (in whole or in part) if, among other things, a safety signal or product quality issue arises.

The word draft is new. The public-inspection version described an enforcement policy; the printed notice calls the document a draft and opens a docket on it. Whether that is a concession to the comment period or a signal that the text will change is not something the notice says. As of this morning the docket holds no documents and no comments.

The conditions, which are the point

The policy document itself, posted on hhs.gov, is longer than the notice and more specific than any of the coverage. It does not simply say that six peptides may be compounded. It says that the department will not act against a pharmacy or physician compounding one of them provided that a list of conditions is met, and the list reads like a specification sheet. In summary, from the document as counsel who have read it describe it:

The conditions of the interim policy, in brief

Condition	What it requires
Who made the bulk substance	The original manufacturer is registered with FDA as a drug establishment and complies with current good manufacturing practice; its physical location is named on the certificate of analysis. A repackager or reseller in between must document that it validated the manufacturer.
What the certificate shows	Testing consistent with the policy's Appendix B: identity, potency, peptide-related impurities, residual solvents, elemental impurities and microbiological quality, with bacterial endotoxin for the forms that need it.
How identity is proven	Where the policy specifies it, at least two independent analytical procedures resting on different physicochemical principles.
Which molecule, exactly	Appendix B fixes each substance by amino-acid sequence, structure, molecular weight and formula, and by salt form: acetate for five of the six, free base for semax.
Which forms	A route table, substance by substance. BPC-157 acetate in four forms; KPV acetate topical and oral; semax free base intranasal only; TB-500, MOTS-c and epitalon acetate in two forms, epitalon in intermittent courses.
One substance per product	A single listed peptide per compounded product. Combinations fall outside the policy.
Oral forms	Documentation that the specific oral formulation has adequate bioavailability in humans.
Devices	The only device that may be co-packaged is an FDA-cleared syringe.
Who it is for	Compounded against a prescription for a named individual, under section 503A; no office stock, no wholesale.
Reporting and labeling	Reports to FDA and the state of the products compounded, serious adverse events and quality problems, through MedWatch; labeling that tells the user how to report and states This is a compounded drug product. Not for resale.

Read that table as a chemist rather than as a lawyer and one thing stands out. The department has written down, for the first time in any official document about these six molecules, what it thinks adequate documentation of a peptide bulk substance looks like: a named, registered, inspected manufacturer; identity by two orthogonal methods; purity, related impurities, residual solvents, elemental impurities, microbiological quality and endotoxin on the certificate; the sequence, the salt form and the formula fixed in an appendix. That is the standard a pharmacy must now meet to be left alone. It is also, almost line for line, the set of questions this library has been telling researchers to ask of any certificate: what it should contain, how identity is confirmed, what the impurity table means, why endotoxin matters, why the salt form is part of the identity.

What was said this week

The notice landed in a crowded week, and the record around it is worth setting down in order.

• October 15. A group of senators led by Indiana's Jim Banks wrote to the acting FDA commissioner about online sellers who, in the letter's words, use research-use-only labeling to sell unapproved drugs, asking FDA to work with Customs and Border Protection and other agencies against them. The letter cites America's Poison Centers data showing a 265% rise in exposures involving counterfeit versions of one investigational molecule in the first four months of 2026 against the last four of 2025. That molecule is the subject of eleven civil suits this library has followed; it is not one of the six.
• October 16. The Partnership for Safe Medicines filed a citizen petition asking FDA not to permit compounding of the six peptides, calling them untested and poorly defined. The petition describes buying five vials of unapproved peptides through telehealth services within 45 days, from pharmacies not licensed for the state they shipped to.
• October 28. The notice was filed. The Associated Press, citing six people familiar with its development, reported that most of FDA's scientific staff opposed the policy and had limited input in drafting it, that the document was primarily written at HHS, and that FDA drug staff had warned it could undermine the agency's long-standing mission of keeping unsafe health products off the U.S. market. The Secretary's statement said the policy provides patients with a more controlled alternative and that he had determined the change advances patient choice and freedom. A former FDA official, Peter Lurie of the Center for Science in the Public Interest, was quoted in opposition; the American Academy of Peptide Medicine, which had met with the White House regulatory office on October 21, in support.
• October 30. Publication. Fourteen days to comment.

One line in the policy document deserves its own paragraph. Among the reasons the department gives for acting, counsel who have read it report an expectation that a regulated channel will discourage widespread use of certain RUO peptides supplied by foreign manufacturers. The department, in other words, has named the research-labeled market as the thing it is building an alternative to. That is consistent with the senators' letter, with FDA's August warning letters, and with the Secretary's own remarks about products from abroad. It is the clearest statement yet of how Washington sees the research channel: not as a laboratory supply chain with its own legitimate purpose, but as the gray market a regulated channel is meant to drain.

What this means for research-labeled products

In law, nothing has moved. The policy is confined to section 503A compounding, and a research-labeled vial is exactly where it was on Monday: an article whose legal character depends on its intended use, read from everything around it. Our compliance series sets out what the label means and how sellers undo it.

In practice, two things have changed, and both cut the same way.

First, there is now a published benchmark for documentation. When a regulator, a court, a journalist or a customer asks what adequate evidence of identity and quality looks like for BPC-157 as a bulk substance, the answer is no longer a matter of opinion; it is Appendix B. A research supplier whose certificate shows an HPLC trace and a mass, and nothing about the manufacturer, the salt form, the related impurities, the solvents or the endotoxin, is now measurably short of a standard the government has written down. That is not a legal obligation on the research market. It is a comparison the research market will be held to anyway.

Second, the department has said in its own document that one purpose of the policy is to draw demand away from research-labeled products from abroad. A supplier whose business depends on the human-use demand the policy is aimed at should read that sentence twice. A supplier whose products are sold, described and documented for laboratory use has a different question to answer, which is whether its documentation would survive being set beside Appendix B. The honest answer, for most of this market, is not yet. The library's certificate guide, the net peptide content and water content articles, and the mass match tool exist so that a researcher can make that comparison on any certificate, from any supplier.

What to watch

• November 13. The docket closes. Who files, and what the petition's authors file, will show whether this goes to court. An enforcement-discretion decision is, under Heckler v. Chaney, presumptively unreviewable, which makes a challenge hard and the policy's protection equally hard to enforce.
• The final text. The notice now calls the policy a draft. If the posted document changes after the comment period, the conditions in the table above are the ones to compare.
• State boards of pharmacy. The policy binds none of them. At least one state board had already sent warning letters about peptide compounding before the notice; the first board to say it will not follow HHS will set the pattern.
• FDA's own voice. The policy is framed entirely as the department's. FDA has not said where it stands, and the briefing documents its reviewers wrote for July still say what they said.
• The citizen petition. FDA owes a response within 180 days of filing, which is mid-April 2027, unless it answers sooner.
• The other side of the line. The next warning letters to research-labeled sellers, and whether they begin to cite Appendix B.

Frequently asked questions

When does the comment period close?

Fourteen days after publication, which is November 13, 2026. Comments go to docket HHS-OASH-2026-0496 at regulations.gov. As of the morning of October 30 the docket held no documents and no comments.

Is the policy in force now?

It is a statement that HHS does not intend to take enforcement action, effective on the department's say-so, and it says it binds no one. The printed notice calls the document a draft and invites comment. It is not a rule and not an approval.

What does a pharmacy have to show to be covered?

A registered, inspected original manufacturer named on the certificate; a certificate consistent with Appendix B covering identity, potency, related impurities, residual solvents, elemental impurities, microbiological quality and endotoxin; the exact substance and salt form; one substance per product; a prescription for a named individual; reporting through MedWatch; and the required labeling. The table above summarizes the list.

Does any of this change the status of research-labeled peptides?

Not in law. In practice it publishes a documentation standard the research market will be compared against, and it states that drawing demand away from research-labeled products from abroad is part of the policy's purpose.

Did FDA agree with the policy?

The policy is written as the department's, not the agency's. The Associated Press reported, citing six sources, that most FDA scientific staff opposed it and had limited input. FDA's briefing documents for the July advisory meeting recommended against each of the nominated substances.

Sources & Further Reading

1. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances; notice of availability. 91 FR 68526–68527, October 30, 2026, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496, RIN 0910-ZD94. Policy document at hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf.
2. regulations.gov, Docket HHS-OASH-2026-0496: documents and comments as listed on the morning of October 30, 2026 (none).
3. Hyman, Phelps & McNamara. The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion … Not the Finish Line. FDA Law Blog, October 2026. A summary of the policy's conditions, Appendix A and Appendix B by counsel who have read the document.
4. Perrone M. FDA scientists opposed the … effort to ease peptides access. Associated Press, October 28, 2026 (carried by PBS NewsHour, ABC News and others).
5. Office of Senator Jim Banks. Banks Urges FDA to Crack Down on Illicit "Research Use Only" Drugs. Press release and letter to the Acting Commissioner of Food and Drugs, October 15, 2026.
6. Partnership for Safe Medicines. Citizen petition to the Food and Drug Administration regarding compounding of six peptides, filed October 16, 2026; announcement of October 26, 2026.
7. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: FDA briefing documents, Docket FDA-2025-N-6895.
8. Office of Information and Regulatory Affairs. RIN 0910-ZD94, Interim Access Policy for Compounding Using Certain Peptides: EO 12866 meeting of October 21, 2026; concluded October 27, 2026. reginfo.gov.
9. Heckler v. Chaney, 470 U.S. 821 (1985).

Cosmic Peptides. (2026, October 30). Fourteen days on the docket: the peptide policy is published, and this is what it requires. Cosmic Peptides Research Library. Retrieved October 30, 2026, from https://cosmicpeptides.com/research/perspectives/fourteen-days-on-the-docket

@misc{cosmicpeptides_research_perspectives_fourteen_days_on_the_docket,
  author       = {{Cosmic Peptides}},
  title        = {Fourteen days on the docket: the peptide policy is published, and this is what it requires},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = oct,
  url          = {https://cosmicpeptides.com/research/perspectives/fourteen-days-on-the-docket},
  urldate      = {2026-10-30},
  note         = {Last reviewed 2026-10-30}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Fourteen days on the docket: the peptide policy is published, and this is what it requires
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/10/30
UR  - https://cosmicpeptides.com/research/perspectives/fourteen-days-on-the-docket
Y2  - 2026/10/30
LA  - en
ER  -